FDA panel to meet October 1 on Southern Hemisphere flu vaccine strains
The Vaccines and Related Biological Products Advisory Committee will convene to discuss and recommend strain selections for the 2027 Southern Hemisphere flu season.
The FDA's Vaccines and Related Biological Products Advisory Committee is scheduled to hold an open session on October 1, 2026. The committee will discuss strain selection for influenza virus vaccines for the 2027 Southern Hemisphere influenza season and provide recommendations.1
The meeting announcement, posted October 1, 2026, does not provide further detail on the specific candidate strains under consideration, the agenda's other components, or the names of committee participants beyond confirming the session's focus on strain selection for the upcoming Southern Hemisphere season.
No additional milestones, follow-up actions, or downstream regulatory steps are specified in the announcement itself.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.